Jana Schilder

  • Home
  • About
  • Services
    • Corporate Social Responsibility & Crisis PR
    • Internal / Employee Communications
      • Change Management
      • M&A / New Corporate Leadership
    • Marketing Communications
      • Video Testimonials
      • Newsletters, Client / Customer Communications
      • Events
      • Websites, Intranets, Social Media
      • Sales Training and Presentation Skills Enhancement
    • Media Relations
      • Generating News
      • Thought Leadership Writing (Op-Eds & White Papers)
      • Media Training
      • Crisis Communications / Reputation Management
  • Case Studies
  • People
    • Jana Schilder
    • Brian Kilgore
    • Robert Picard
    • Neil Bruce
    • Tom Eansor
  • News
  • Resources
    • Clients In The News
    • Websites
    • Our Articles
  • Contact Us

A Multinational Pharmaceuticals Group Went Back to the Lab to Protect Public Health before Launching a New Drug

CLIENT

A multinational pharmaceuticals group planned to launch a new drug in the European market.

PROBLEM

The drug was developed to prevent obesity within the population. Early research showed that besides the benefits offered, potentially it could have negative side effects. The drug had to be seen to be medically safe by regulatory authorities before being granted a licence.

OPPORTUNITY

A First Principles consultant worked with the management team on identifying and managing issues while preparing a marketing strategy.

DELIVERABLES

The senior management team were guided through an issues/crisis management plan. Risk assessment was made on the current research results. Issues threatening the drug’s approval, including any negative side effects, were carefully studied.

Where appropriate, we recommended that further product research be done to protect public health and the company’s reputation.

Once the research was completed, we gave advice on how to present the new drug to an influential authority who would decide whether the drug could be marketed across Europe.

RESULTS

The drug was able to meet compliance standards and was granted a licence to be marketed by the European Commission.

 

Latest News

  • Law firms tinkering as business model under stress
  • How to be more creative
  • With Cisco’s $100M investment in global innovation centre, Toronto is now no. 2 to Silicon Valley
  • The threat to your business is not your competition
  • Here’s how to make viral videos, from promoters of ‘Devil’s Due’

Jana Schilder’s Tweets

Tweets by @JanaSchilder
CyberChimps ©2023